Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

971 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.
Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GL, Allan JM. Fordham SE, et al. Among authors: jamieson d. Blood Adv. 2018 May 22;2(10):1157-1169. doi: 10.1182/bloodadvances.2017015214. Blood Adv. 2018. PMID: 29789314 Free PMC article.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.
Dent BM, Ogle LF, O'Donnell RL, Hayes N, Malik U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FE, Jamieson D. Dent BM, et al. Among authors: jamieson d. Int J Cancer. 2016 Jan 1;138(1):206-16. doi: 10.1002/ijc.29680. Epub 2015 Aug 19. Int J Cancer. 2016. PMID: 26178530 Free PMC article.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Drew Y, et al. Among authors: jamieson d. Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22. Br J Cancer. 2016. PMID: 27002934 Free PMC article. Clinical Trial.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R. Jamieson D, et al. Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28. Eur J Cancer. 2016. PMID: 27693888 Free article. Clinical Trial.
Temporary Single-Cell Coating for Bioprocessing with a Cationic Polymer.
Ribeiro RDC, Pal D, Jamieson D, Rankin KS, Benning M, Dalgarno KW, Ferreira AM. Ribeiro RDC, et al. Among authors: jamieson d. ACS Appl Mater Interfaces. 2017 Apr 19;9(15):12967-12974. doi: 10.1021/acsami.6b16434. Epub 2017 Apr 4. ACS Appl Mater Interfaces. 2017. PMID: 28323412 Free PMC article.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Drew Y, et al. Among authors: jamieson d. Br J Cancer. 2016 Jun 14;114(12):e21. doi: 10.1038/bjc.2016.133. Epub 2016 May 26. Br J Cancer. 2016. PMID: 27228289 Free PMC article. No abstract available.
971 results